{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010978","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.697414+00:00","generated_at":"2026-06-17T09:05:37.926155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Biopharma reports FY2022 revenue $67.8M, cash runway into H2 2024; plans luvelta Phase 2/3 in Q2 2023","bullets":["Cash and investments of $302.3M plus Vaxcyte stock valued at $32.0M provide cash runway into H2 2024.","Revenue for FY2022 was $67.8M, up from $61.9M in FY2021, driven by collaboration payments.","Total operating expenses were $196.7M, up from $160.4M, with R&D at $137.2M and G&A at $59.5M.","Plans to initiate Phase 2/3 registration-directed study of luvelta in platinum-resistant ovarian cancer in Q2 2023.","Dr. Anne Borgman appointed Chief Medical Officer in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010978","json":"https://secwatch.observer/filing/0000950170-23-010978.json","markdown":"https://secwatch.observer/filing/0000950170-23-010978.md","text":"https://secwatch.observer/filing/0000950170-23-010978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/stro-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:05:37.926155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"731fe9be16bde417557352b4d0ad9180d2f45e8e","claim":"SUTRO BIOPHARMA, INC. reported financial results for the full year 2022.","evidence_excerpt":"On March 30, 2023, Sutro Biopharma, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}